Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


July 29, 2010
Prevention Is Failing to Target MSM When They’re Young Enough
If we are going to prevent HIV transmission in young men who have sex with men (MSM), we must find strategies to reach them when they are in their early teens. So say researchers who presented a study Monday, July 19, at the XVIII International AIDS Conference in Vienna.
AIDS 2010: Kandy Ferree
Kandy Ferree, president and CEO of the National AIDS Fund, talks with Regan Hofmann, editor-in-chief of POZ, at the XVIII International AIDS Conference in Vienna. (Watch video.)
July 28, 2010
Global Survey: Stigma, Isolation and Discrimination Still Pervasive
HIV-associated stigma, isolation and discrimination remain pervasive problems in the United States and other parts of the world and continue to have profound effects on people’s willingness to disclose their serostatus to key individuals in their lives. This is the finding of a global survey of 2,035 people living with HIV conducted by the International Association for Physicians in AIDS Care (IAPAC) on Thursday, July 22, at the XVIII International AIDS Conference in Vienna.
Universal HIV Treatment Access No Guarantee of Health for Socially Disadvantaged
Socially marginalized people living with HIV, despite universal access to care and treatment, are still dying of AIDS-related illnesses at a high rate, according to a study presented Tuesday, July 20, at the XVIII International AIDS Conference in Vienna.
'Creative and Novel Ideas in HIV Research' Inaugural Grants
Ten recipients have been awarded the inaugural “Creative and Novel Ideas in HIV Research” grants. The grants are funded in partnership with the International AIDS Society (IAS), the U.S. National Institutes of Health and the Centers for AIDS Research, according to an IAS statement. 
HIV Researchers Honored at Vienna AIDS Conference
The International AIDS Society (IAS) and its partners honored 10 researchers with four scientific awards for their innovative global HIV/AIDS research; the awards were presented during the XVIII International AIDS Conference in Vienna, according to an IAS statement. 
July 27, 2010
OM-85 BV: A Bacterial Vaccine Against Respiratory Problems in People with HIV and COPD?
Can a capsule containing bits of eight bacteria decrease rates of recurrent respiratory infections in people living with HIV who also are at high risk for chronic pulmonary disease? According to a small observational cohort study conducted in Milan and reported Thursday, July 22, at the XVIII International AIDS Conference in Vienna, this may be possible.
Low Vitamin D Levels Not Associated With HIV Drugs
Low vitamin D levels in people with HIV were not associated with any particular antiretroviral (ARV) medication, nor with signs of bone loss, according to a study presented Wednesday, July 21, at the XVIII International AIDS Conference (IAC) in Vienna.
Elly Katabira Is New President of International AIDS Society
The International AIDS Society (IAS) has named Elly Katabira, MD, its new president and Francoise Barre-Sinoussi, PhD, as president-elect, according to an IAS statement. 
International AIDS Society Honors Jack Whitescarver
The International AIDS Society (IAS) has presented its inaugural IAS Presidential Award to Jack Whitescarver, PhD, associate director for AIDS research at the National Institutes of Health (NIH) and director of the NIH Office of AIDS Research (OAR), according to an IAS statement. 
July 26, 2010
HPV Cancer Vaccine Effective for Heterosexual, Gay and Bisexual Men
Gardasil, an approved vaccine active against four strains of human papillomavirus (HPV), can substantially reduce the risk of cancerous and non-cancerous varieties of anal and penile lesions in men, according to data from a large clinical trial reported Friday, July 23, at the XVIII International AIDS Conference in Vienna. Importantly, the study enrolled a sizeable number of men who have sex with men (MSM) and demonstrated a significant reduction in the number of pre-cancerous anal lesions caused by HPV.
Tibotec Submits Approval Application for HIV Non-Nuke Rilpivirine
Tibotec Therapeutics, a subsidiary of Johnson & Johnson, announced on Monday, July 26, that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for rilpivirine (TMC278), its experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). Tibotec is seeking approval of rilpivirine as a once-a-day option for patients starting HIV treatment for the first time.
Study Finds PrEP Is Safe in Gay and Bi Men
Pre-exposure prophylaxis (PrEP) with tenofovir (found in Viread, Truvada and Atripla) is safe for men who have sex with men (MSM), according to a U.S. study presented Friday, July 23, at the XVIII International AIDS Conference (IAC) in Vienna.

Obama Recommits to HIV at Vienna AIDS Conference
President Barack Obama recommitted his administration to the fight against HIV at the XVIII International AIDS Conference (IAC) in Vienna, Reuters reports.
July 23, 2010
Longer Duration of HIV Infection Might Increase the Risk of Brain Disorders
The longer a person lives with HIV, the more he or she might be at risk of neurocognitive impairment (NCI), according to a study presented Thursday, July 22, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna. This is one explanation offered by Igor Grant, MD, from the University of California at San Diego, and his colleagues from the CHARTER study, for their finding that NCI is more prevalent now, in the modern era of combination antiretroviral therapy (CART) than in the pre-CART era.
Circumcision Unlikely to Have Major HIV Prevention Benefit Among Gay Men
Circumcising men who have sex with men (MSM) is likely to have a negligible effect on the rate of new HIV cases in the United States, according to a survey conducted in San Francisco in 2008 and reported Thursday, July 22, at the International AIDS Conference in Vienna.
More Details of TBR-652’s Antiviral and Anti-Inflammatory Potential Reported
TBR-652, which blocks CCR5 receptors and is being developed by Tobira Therapeutics, not only has promising activity against HIV but may also have important disease-reducing anti-inflammatory properties, according to an update from a Phase II study of the drug reported Monday, July 19, at the XVIII International AIDS Conference in Vienna.
Nearly 75 Percent of People With HIV Might Have Bone Problems
Roughly half of people living with HIV in one study had mild to moderate bone mineral loss (osteopenia) and another one quarter had more severe bone mineral loss (osteoporosis), according to data presented Thursday, July 22, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
New HIV/AIDS Policy Proposal for IV Drug Users
A new report from the International AIDS Society (IAS) advocates for broader use of highly active antiretroviral therapy (HAART) among intravenous drug users, both for their own health and to restrict HIV transmission, according to an IAS statement.
July 22, 2010
POZ Blogs: AIDS 2010
POZ bloggers offer their perspectives on the XVIII International AIDS Conference in Vienna.

Below are links to their blog posts:

Closing The Page On Vienna, Looking Toward Challenges In DC:
"Before the U.S. & DC community partners accepted the IAC Globe, I addressed the audience."

Microbicides, Men and HIV:
"When Gwenn and I were discussing this news item, my first thought was a personal one ... But she made a very astute point, 'Once again, the woman has to bear all the responsibility.'"

All That We Desire:
"Navigating sexual desire, encounters and relationships in a world with HIV/AIDS was the topic of several sessions."

Mobilize Against the Viral Holocaust, AIDS Activists Implore in Vienna:
"AIDS activists raised alarm over the lack of treatment imperiling more than 10 million HIV-positive people worldwide..."

Also, here's a link to a post by Paurvi Bhatt at the Levi Strauss blog: We All Want to Work.
ViiV HIV Integrase Inhibitor Performing Well in First-Time Treatment Study
The experimental integrase inhibitor S/GSK1349572 (S/GSK-572) reduced viral load to undetectable levels in 96 percent of first-time HIV treatment takers receiving 10 milligrams (mg) of the drug in a clinical trial, compared with 60 percent of those receiving standard doses of Sustiva (efavirenz), according to preliminary 16-week data reported Friday, July 22, at the XVIII International AIDS Conference in Vienna.
Reyataz/Isentress Combo Spares Norvir and Nukes, But Is Integrase Resistance a Concern?
A regimen consisting of Reyataz (atazanavir) and Isentress (raltegravir)—used without low-dose Norvir (ritonavir) boosting or any nucleoside reverse transcriptase inhibitors (NRTIs)—is performing well in a clinical trial involving Norvir-boosted Reyataz plus Truvada (tenofovir plus emtricitabine) as a comparison, according to preliminary data reported Thursday, July 22, at the XVIII International AIDS Conference in Vienna. Of potential concern, however, are four cases of resistance to Isentress that have been documented thus far.
Health Care Providers and People With HIV Not Communicating Effectively
Many people living with HIV and their health care providers are not communicating effectively about critical health-related conditions, according to the results of an international survey released on Tuesday, July 20, at the XVIII International AIDS Conference in Vienna.
Rilpivirine Has Similar Efficacy and Better Tolerability Than Sustiva
Rilpivirine (TMC278) was similar to Sustiva (efavirenz) in two large clinical trials but demonstrated much fewer central nervous system (CNS) side effects, according to a presentation Thursday, July 22, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
Male Circumcision Promoted for HIV Prevention in Africa
Leaders at the XVIII International AIDS Conference in Vienna are promoting male circumcision as a “proven, cost-effective method” for HIV prevention in Africa, according to a Population Services International (PSI) statement.
Extended-Release Viramune Has Comparable Safety and Efficacy to Standard Viramune
Viramune XR—an extended-release version of the nucleoside reverse transcriptase inhibitor nevirapine (NNRTI)—is comparable to standard twice-daily dosing of the available immediate-release formulation of the drug, according to study results reported Thursday, July 22, at the XVIII International AIDS Conference in Vienna.
UNAIDS Launches High Level Commission on HIV Prevention
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has launched a new High Level Commission on HIV Prevention, according to a UNAIDS statement.
Possibly No Survival Benefit to Starting HIV Treatment at CD4s of 500 or More
People who start antiretroviral therapy early—when their CD4 cell counts are 500 or greater—might not significantly lower their risk of AIDS or death over a three-year period compared with people who wait to start therapy when until their CD4 counts drop below 500. These data were presented Thursday, July 22, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
Once-Daily Prezista/Norvir Monotherapy Largely Effective Over 96 Weeks
People taking once-daily Norvir (ritonavir)-boosted Prezista (darunavir) monotherapy were able to maintain control over HIV for 96 week about as well as people who switched to Novir-boosted Prezista plus two nucleoside reverse transcriptase inhibitors (NRTIs). These data were presented Thursday, July 22, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
Abacavir/Lamivudine Equivalent to Tenofovir/Emtricitabine in Canadian Cohort Study
People taking an antiretroviral (ARV) combination including abacavir and lamivudine were just as likely to maintain an undetectable viral load over one year as people taking a combination including tenofovir and emtricitabine—regardless of their initial HIV levels. These results, from a Canadian HIV cohort, were presented Thursday, July 22, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
July 21, 2010
Microbicide Success Story: What It Means and Where We Go Next
We know now that a tenofovir microbicidal gel can reduce HIV transmission in women by up to 54 percent and herpes simplex virus (HSV2) by about half. What else have we learned, however, about how tenofovir accomplishes this feat? Moreover, what do the CAPRISA 004 results mean for other prevention trials underway, and how long might it take before this microbicide makes it into the hands of women around the world?
Non-AIDS Cancers Occurring at Earlier Age Among People With HIV
Not only are people living with HIV more likely to be diagnosed with a cancer not typically associated with AIDS, but they are also more likely to be diagnosed with a malignancy at a younger age. These are the sobering findings of a study conducted in Atlanta and reported Wednesday, July 21, at the XVIII International AIDS Conference in Vienna.
Hep C Treatment Effective in HIV Patients With Normal Liver Enzymes
People infected with HIV and hepatitis C virus (HCV) who have normal liver alanine transaminase (ALT) levels may benefit from pegylated interferon/ribavirin treatment, according to new data presented Tuesday, July 21, at the XVIII International AIDS Conference in Vienna. These results are important, as people with HCV and normal ALT levels are frequently told that treatment is not necessary.
Advice on Speeding the Search for an HIV Vaccine
A new report by the Global HIV Vaccine Enterprise (GHVE) outlines the challenges in developing an AIDS vaccine and recommends ways to accelerate research, according to a GHVE statement. 
Innovation Continues in Global AIDS Response
The expansion of HIV treatment access, the use of antiretrovirals to prevent HIV infections and the pursuit of a cure for HIV are three of the major themes emerging at the XVIII International AIDS Conference (IAC) in Vienna, according to an IAC statement. 
MACS: Childhood Sex Abuse and Victimization Linked to Increased HIV Risk
Gay and bisexual men enrolled in the Multicenter AIDS Cohort Study (MACS) who reported sexual abuse and social shaming in childhood experience psychosocial health problems later in life known to substantially increase the risk of HIV infection, according to data reported Wednesday, July 21, at the XVIII International AIDS Conference in Vienna.
PEPFAR Saved $323M Using Generic HIV Drugs
The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) saved slightly more than $323 million from 2005 to 2008 by using generic HIV drugs to treat people living with the virus, according to a study published in the Journal of the American Medical Association
Full-Scale HIV Treatment and Prevention Could Save Millions of Lives
A full-scale rollout of HIV treatment and available prevention methods could avert 6.75 million new infections and 4.7 million AIDS-related deaths in China and South Africa alone, according to a study presented Wednesday, July 21, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
AIDS 2010: Kevin Frost
Kevin Frost, CEO of amfAR, talks with Regan Hofmann, editor-in-chief of POZ, at the XVIII International AIDS Conference in Vienna. (Watch video.)
Aging Might Have a Smaller Impact on Immune Function Than Suspected
People who are 55 or older have roughly the same degree of immune activation as younger people, according to a small study presented Wednesday, July 21, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna. This runs counter to speculation that aging with HIV significantly worsens immune activation.
AIDS 2010: Op-Eds
During the XVIII International AIDS Conference in Vienna, both critics and supporters have written op-eds on U.S. HIV funding in Africa, including Desmond Tutu and Ezekiel Emanuel.
AIDS 2010: Regan Hofmann
Regan Hofmann, editor-in-chief of POZ, speaks with Ron Valdiserri from the Department of Health and Human Services during the XVIII International AIDS Conference in Vienna. (Watch video.)
July 20, 2010
Tenofovir Microbicidal Gel Significantly Cuts HIV Infection Rate
After decades of research, a microbicidal gel—in this case made from the antiretroviral drug tenofovir—has finally proved effective in preventing transmission of HIV in women, cutting the overall infection rate by 39 percent. These data were reported Tuesday, July 20, at the XVIII International AIDS Conference in Vienna and were published online July 19 in the journal Science.
5.2 Million People With HIV in Low- and Middle-Income Countries Now on Treatment
An estimated 5.2 million people in low and middle-income countries were receiving lifesaving HIV treatment at the end of 2009, according to a World Health Organization (WHO) update on Monday, July 19, at the XVIII International AIDS Conference (IAC) in Vienna.
At Least 31 Countries Deporting People Living With HIV
At least 31 countries still deport people living with HIV, according to a survey of 197 countries conducted by Deutsche AIDS-Hilfe and Human Rights Watch reported on Tuesday, July 20, at the XVIII International AIDS Conference in Vienna.
Viramune Boosts Hep C Treatment Efficacy in People With HIV
People coinfected with HIV and hepatitis C virus (HCV) who receive Viramune (nevirapine) may respond better to pegylated interferon/ribavirin HCV treatment compared with those receiving Kaletra (lopinavir/ritonavir), according to a retrospective study reported Tuesday, July 20, at the XVIII International AIDS Conference in Vienna.
POZ Cocktail Reception in Vienna
POZ held a cocktail reception in Vienna on July 19 during the XVIII International AIDS Conference to showcase the In the Face of Affliction exhibit by photographer Joan Lobis Brown.
HIV/HCV Coinfection Further Increases Risk of Bone Fractures
Compared with people living with HIV, people coinfected with HIV and hepatitis C virus (HCV) appear to face an even higher risk of bone fractures, according to new data reported Tuesday, July 20, at the XVIII International AIDS Conference in Vienna.
Leaders in Vienna Seek $20B for the Global Fund
Delegates and speakers at the XVIII International AIDS Conference (IAC) in Vienna are calling on global leaders to commit at least $20 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria at the fund’s replenishment meeting in October, according to an IAC statement.
New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains
An experimental integrase inhibitor being developed by Shionogi Pharmaceuticals and ViiV Healthcare—currently dubbed S/GSK-572—effectively reduces HIV levels in at least some people with HIV resistant to Isentress (raltegravir). These findings were reported in a presentation Monday, July 19, at the International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
HIV Cases in Young People Are Falling Around the World
The number of young people living with HIV around the world is falling, according to a Joint United Nations Programme on HIV/AIDS (UNAIDS) study presented Tuesday, July 20, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
AIDS2010: Fewer Malignancies Seen in Those Taking Selzentry
People taking the entry inhibitor Selzentry (maraviroc) were no more likely to develop cancer than people taking either Sustiva (efavirenz) or a placebo, according to a study presented Tuesday, July 20, at the XVIII International AIDS Conference (IAC), taking place July 18 to 23 in Vienna.
July 19, 2010
Strategies for a Cure Reviewed in Vienna
True to tradition, several world-renowned key opinion leaders opened this year’s International AIDS Conference, being held July 18 to 23 in Vienna, with a detailed review of the state of the HIV epidemic. Among the speakers was Sharon Lewin, FRACP, PhD, director of the infectious diseases unit at The Alfred Hospital in Melbourne, Australia, who made a provocative call to move full-steam ahead with strategies to cure HIV.
Kaletra/Isentress Shows Promise as HIV Nuceleoside-Sparing Regimen for First-Line Treatment
A nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen consisting of Kaletra (lopinavir and ritonavir) plus Isentress (raltegravir) is comparable with a standard regimen consisting of Kaletra plus Truvada (tenofovir and emtricitabine) in people living with HIV starting antiretroviral (ARV) therapy for the first time, according to 48-week study results reported Monday, July 19, at the XVIII International AIDS Conference in Vienna.
Study: Global HIV Rates Among MSM Are Soaring
Global HIV rates among men who have sex with men (MSM) are soaring, according to a Johns Hopkins/World Bank study of HIV epidemics among MSM worldwide in 2010.
CDC: HIV an Epidemic for Heterosexuals in Inner Cities
HIV prevalence among heterosexuals in U.S. inner cities is 2.1 percent, according to a study by the Centers for Disease Control and Prevention (CDC) and reported by The Wall Street Journal.
Switch From Sustiva to Intelence Reduces Central Nervous System Side Effects
People with central nervous system (CNS) side effects, who switched from Sustiva (efavirenz) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to Intelence (etravirine) plus two NRTIs, had a significant reduction in those side effects. These data were reported in a scientific poster presentation Monday, July 19, at the International AIDS Conference (IAC), being held July 18 to 23 in Vienna.
Argos’s Dendritic Cell Therapy Reduces HIV During Treatment Interruption
A dendritic cell therapy by Argos Therapeutics, called AGS-004, was able to keep virus at least partially under control during a 12-week antiretroviral (ARV) treatment interruption, according to a study presented Monday, July 19, at the International AIDS Conference (IAC), being held July 18 to 23 in Vienna.
AIDS2010: Protease Inhibitor-to-Isentress Switch is Effective, Lipid Friendly
Replacing a Norvir (ritonavir)?boosted protease inhibitor with Isentress (raltegravir) may be an effective option—with improvements in blood lipid levels—for HIV-positive individuals with undetectable viral loads, according to the results of two Spanish studies reported Monday, July 19, at the XVIII International AIDS Conference in Vienna.
Preliminary Results Suggest Good Safety and Adherence Profile for PrEP
People taking either daily or intermittent pre-exposure prophylaxis (PrEP) to prevent HIV infection had few side effects and relatively good adherence to these regimens, according to data presented Monday, July 19, at the XVIII International AIDS Conference (IAC) being held July 18 to 23 in Vienna.
July 18, 2010
amfAR Vienna Life Ball Gala
On July 17, opening night of the XVIII International AIDS Conference in Vienna, amfAR, The Foundation for AIDS Research, hosted its first gala in the region. 
July 16, 2010
Earlier Treatment Cuts Risk of Death by 75 Percent in Haitian Study
People who begin antiretroviral (ARV) therapy before their CD4 counts fall to 200 or less have a 75 percent reduction in the risk of death compared with people who wait to start treatment until their CD4 count is below 200. These data, from a Haitian study, were published July 15 in The New England Journal of Medicine.
In The Face of Affliction
A special exhibit of Joan Lobis Brown’s work will be on display July 18-23 in Vienna during the XVIII International AIDS Conference at the Hotel Altstadt. (The image featured in this photo graces the cover of the July/August 2010 issue of POZ.)
Global HIV/AIDS Funding Faces Scrutiny
As a result of the global recession, HIV/AIDS funding worldwide is being scrutinized for increased efficiencies, Reuters reports.
July 15, 2010
Merck Terminates Development of Its HIV Entry Inhibitor, Vicriviroc
Merck announced July 14 that it is abandoning development of vicriviroc, the company’s CCR5-blocking HIV entry inhibitor candidate. In a statement, Merck explained: “This decision was based on the overall clinical data from Phase III trials in treatment-experienced patients and a recently completed Phase II trial in treatment-naive patients.”
July 14, 2010
Activist Group Claims HIV Cure Is Closer Than Many Think
The AIDS Policy Project, in Philadelphia, has issued a report contending that a cure for AIDS may be closer to fruition than most people think, but that poor research funding is holding it back.
July 13, 2010
White House Reveals National HIV/AIDS Strategy
The White House has released its national strategy to fight HIV/AIDS, which is aimed at reducing the number of new infections and providing high quality care for those living with the virus, The New York Times reports. (Watch video.)
July 09, 2010
Newly Discovered Antibody Kills Up to 91 Percent of HIV Strains
U.S. government scientists have discovered three potent new antibodies, one of which can neutralize up to 91 percent of all HIV strains. These discoveries were published online July 8 in Science and were reported by The Wall Street Journal. Though the scientists acknowledge that their findings represent a hopeful step forward, they caution that it will take a lot of time and effort before they can be translated into something that will prevent or treat HIV infection.
July 08, 2010
Increased Mortality Seen in Women With Kidney Disease Despite HIV Treatment
Women with chronic kidney disease (CKD) who start antiretroviral (ARV) therapy have a two-fold increased risk of mortality compared with HIV-positive women who don’t have CKD, according to a study published online July 6 in the Journal of Acquired Immune Deficiency Syndromes.
July 07, 2010
HIV Stem Cell Therapy in Mice Is Successful
Researchers are reporting that a new method for altering the genes of immune cells to make them resistant to HIV infection was a success in mice. The study was reported online on July 2 in the journal Nature Biotechnology.
July 06, 2010
Boosting Dose of Norvir Doesn’t Affect Insulin
Norvir (ritonavir)—when given at the type of low doses used to boost blood levels of other protease inhibitors—does not affect how the body uses insulin, according to a study published online June 30 in the Journal of Acquired Immune Deficiency Syndromes.
July 02, 2010
Atripla Co-pay Program to Cover More People
Gilead Sciences and Bristol-Myers Squibb have announced that the co-payment assistance program for Atripla (containing efavirenz, tenofovir and emtricitabine) has been revised and will essentially benefit all people living with HIV with private health insurance who pay any out-of-pocket co-payment fees. The greatly enhanced co-payment program went into effect July 1.
July 01, 2010
Vienna Declaration Seeks Changes to “War on Drugs”
A global drive has been launched for signatories to the Vienna Declaration.
Bill Clinton to Be Honored at Life Ball in Vienna
Actresses Elizabeth Hurley and Whoopi Goldberg along with former President Bill Clinton will be guests of honor at the 18th annual Life Ball in Vienna.
HIV-Positive People on Abacavir Don’t Have More Inflammation
HIV-positive women and men do not appear to have increased signs of cardiovascular inflammation when they take abacavir (found in Ziagen, Epzicom and Trizivir), according to a study published online June 25 in the journal AIDS. These results stand in contrast to a couple of previous studies that found not only higher levels of inflammatory proteins in abacavir takers, but also an increased risk for heart attacks.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.